Katja Mercer-Chalmers-Bender

Dr. Katja Mercer-Chalmers-Bender

Institute of Forensic Medicine, Department of Biomedical Engineering, University of Basel, 4056 Basel, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2010 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
AWAnnette Wintermeyer
Annette Wintermeyer
IMInes Möller
Ines Möller
MTMario Thevis
Mario Thevis
MJMartin Jübner
Martin Jübner
JBJustus Beike
Justus Beike
KMKatja Mercer-Chalmers-Bender
Katja Mercer-Chalmers-Bender

24 September 2010 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
IMInes Möller
Ines Möller
AWAnnette Wintermeyer
Annette Wintermeyer
KMKatja Mercer-Chalmers-Bender
Katja Mercer-Chalmers-Bender
MJMartin Jübner
Martin Jübner
ATAndreas Thomas
Andreas Thomas
MTMario Thevis
Mario Thevis

13 May 2015 in Brain
Verified
Journal Article
Open access
PDF file
BBBenjamin Becker
Benjamin Becker
DWDaniel Wagner
Daniel Wagner
PKPhilip Koester
Philip Koester
MTMarc Tittgemeyer
Marc Tittgemeyer
KMKatja Mercer-Chalmers-Bender
Katja Mercer-Chalmers-Bender
JDJoerg Daumann
Joerg Daumann
Drug addiction is a chronic, relapsing brain disorder. The identification of biomarkers that render individuals vulnerable for the transition from occasional drug use to addiction is of key importance to develop early intervention strategies. The aim of the present study was to prospectively assess brain structural markers for escalating drug use in two independent samples of occasional amphetamine-type stimulant users. At baseline occasional users of amphetamine and 3,4-methylenedioxymethamphetamine (cumulative lifetime use ≤10 units) underwent structural brain imaging and were followed up at 12 months and 24 months (Study 1, n = 38; Study 2, n = 28). Structural vulnerability markers for escalating amphetamine-type drug use were examined by comparing baseline grey matter volumes of participants who increased use with those who maintained or reduced use during the follow-up period. Participants in both samples who subsequently increased amphetamine-type drugs use displayed smaller medial prefrontal cortex volumes and, additionally, in the basolateral amygdala (Study 1) and dorsal striatum (Study 2). In both samples the baseline volumes were significantly negatively correlated with stimulant use during the subsequent 12 and 24 months. Additional multiple regression analyses on the pooled data sets revealed some evidence of a compound-specific association between the baseline volume of the left basolateral amygdala and the subsequent use of amphetamine. These findings indicate that smaller brain volumes in fronto-striato-limbic regions implicated in impulsivity and decision-making might render an individual vulnerable for the transition from occasional to escalating amphetamine-type stimulant use.

23 June 2012 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
GWGuido F. Weißhaar
Guido F. Weißhaar
MHMarc Hoemberg
Marc Hoemberg
KMKatja Mercer-Chalmers-Bender
Katja Mercer-Chalmers-Bender
UBUrsula Bangen
Ursula Bangen
PHPeter Herkenrath
Peter Herkenrath
AOAndré Oberthuer
André Oberthuer

1 October 2017 in Journal of Chromatography B
Verified
Journal Article
Closed access
SLSabrina Lehmann
Sabrina Lehmann
TKTobias Kieliba
Tobias Kieliba
JBJustus Beike
Justus Beike
MTMario Thevis
Mario Thevis
KMKatja Mercer-Chalmers-Bender
Katja Mercer-Chalmers-Bender

1 October 2018 in Forensic Science International
Verified
Journal Article
Closed access
UMUlf Meier
Ulf Meier
FDFranz Dussy
Franz Dussy
Eva ScheurerEva Scheurer
Eva Scheurer
KMKatja Mercer-Chalmers-Bender
Katja Mercer-Chalmers-Bender
SHSarah Hangartner
Sarah Hangartner